

A DOCPHOENIX

## **APPL PARTS**

imis .
Internal Misc. Paper
LET
Misc. Incoming Letter
371P
PCT Papers in a 371Application
A
Amendment Including Elections
ABST
Abstract
ADS
Application Data Sheet
AF/D
Affidavit or Exhibit Received
APPENDIX
Appendix
Artifact ARTIFACT
Bib Data Sheet
Claim CLM
Computer Program Listing
CRFL
All CRF Papers for Backfile
•
DIST Terminal Disclaimer Filed
Drawings DRW
<del></del>
Foreign Reference
- oroigir rioloiolioo

Foreign Priority Papers

IDS Including 1449

NPL
Non-Patent Literature
OATH
Oath or Declaration
PET
Petition
RETMAIL
Mail Returned by USPS
SEQLIST
Sequence Listing
SPEC
Specification
SPEC NO
Specification Not in English
TRNA
Transmittal New Application

# **OUTGOING**

CTMS
Misc. Office Action
1449
Signed 1449
892
892
ABN
Abandonment
APDEC
Board of Appeals Decision
APEA
Examiner Answer
CTAV
Count Advisory Action
CTEQ
Count Ex parte Quayle
CTFR

# **INCOMING**

AP.B
Appeal Brief
C.AD
Change of Address
N/AP
Notice of Appeal
PA
Change in Power of Attorney
REM
Applicant Remarks in Amendment
XT/
Extension of Time filed separate

Internal	ECBOX	
Internal	Evidence Copy Box Identification	
SRNT	WCLM	
Examiner Search Notes	Claim Worksheet	
CLMPTO	WFEE	
PTO Prepared Complete Claim Set	Fee Worksheet	
6/26/03		

ECBOX
Evidence Copy Box Identification
WCLM
Claim Worksheet
WFEE
Fee Worksheet

Count Final Rejection

File Wrapper			
File Wrapper Claim			
IIFW File Wrapper Issue Information			
SRFW			



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/807,458	07/05/2001	Carmen Almansa	1604-129	7335
6449	7590 05/31/2002			
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005		EXAMINER		
		SAEED, KAMAL A		
			ART UNIT	PAPER NUMBER
			1626	1
			DATE MAILED: 05/31/2002	8

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application N .	Applicant(s)	
	Office Action Summary	09/807,458	ALMANSA ET AL.	
	Office Action Summary	Examiner	Art Unit	
}	The MAU INC DATE A SALE	Kamal A Saeed	1626	
	The MAILING DATE of this c mmunication appears on the cover sh et with the correspondence address Period for Reply			
	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).			
İ	Status			
İ	1) Responsive to communication(s) filed on			
1		s action is non-final.		
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims			
	4)⊠ Claim(s) <u>1-13 and 20-40</u> is/are pending in the a	application.		
	4a) Of the above claim(s) is/are withdrawn from consideration.			
	5) Claim(s) is/are allowed.			
	6) Claim(s) is/are rejected.			
	7) Claim(s) is/are objected to.			
	8)⊠ Claim(s) <u>1-13 and 20-40</u> are subject to restrictio Application Papers	n and/or election requirement.		
	9)☐ The specification is objected to by the Examiner.			
	10) The drawing(s) filed on is/are: a) accepted	ad or h) Contacted to but he Fuer	-to	
	Applicant may not request that any objection to the	drawing(s) he hold in shovenes. So	niner.	
	11) The proposed drawing correction filed on i	is: a) approved b) disapprov	e 37 CFR 1.85(a).	
	If approved, corrected drawings are required in reply	v to this Office action	ved by the Examiner.	
	12) The oath or declaration is objected to by the Exar			
	Priority under 35 U.S.C. §§ 119 and 120			
	13) Acknowledgment is made of a claim for foreign p	priority under 35 H.S.C. & 110(a)	(d) or (f)	
	a) ☐ All b) ☐ Some * c) ☐ None of:		-(d) or (i).	
	1. Certified copies of the priority documents i	have been received		
	2. Certified copies of the priority documents h		n No	
	3. Copies of the certified copies of the priority	/ documents have been received	lin this National Otal	
	<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>			
	14) Acknowledgment is made of a claim for domestic p	priority under 35 U.S.C. § 119(e)	(to a provisional application).	
A	a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)			
3)	== 100000010 Otalicine(11(3) (1 10-1449) Paper No(S)	5)   Notice of Informal Da	PTO-413) Paper No(s) tent Application (PTO-152)	
U.S.	Patent and Trademark Office O-326 (Rev. 04-01) Office Actio	n Summary	Port of Person No. 0	

#### **DETAILED ACTION**

Claims 1-13 and 20-40 are pending in this application.

This office action supersedes the office action of paper No. 4 which has been entered in the file.

#### Election/Restrictions

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Due to the numerous variables in the claims, e.g. R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, Y etc and their widely divergent meanings, a precise listing of inventive groups cannot be made. The following groups are exemplary:

Group I claim(s) 1-11 drawn in part to compound of the formula I wherein, Y and X are as defined in claim 1, R<sup>1</sup> and R<sup>3</sup> are as defined in claim 1, R<sup>2</sup> is unsubstituted or substituted phenyl or naphthyl, one process for their preparation and one method of use (e.g. treating cancer).

Group II claim(s) 1-11, drawn in part to compound of the formula I wherein, Y and X are as defined in claim 1, R<sup>1</sup> and R<sup>3</sup> are as defined in claim 1, R<sup>2</sup> represents unsubstituted or substituted pyridine, one process for their preparation and one method of use (e.g. treating inflammation).

Group III claim(s) 1-11, drawn in part to compound of the formula I wherein, Y and X are as defined in claim 1,  $R^1$  and  $R^3$  are as defined in claim 1,  $R^2$  represents unsubstituted or substituted pyrazine, pyrimidine or pyridazine, one process for their preparation and one method of use (e.g. treating epilepsy).

Page 3

Application/Control Number: 09/807,458

Art Unit: 1626

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Again, this list is not exhausted, as it would be impossible under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, applicant may choose to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention and examiner will endeavor to group the same. If applicant is unable to elect a single invention, applicant may instead choose to elect a specific compound and examiner will attempt to group it. The claims herein lack unity of invention under PCT Rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The compounds claimed contain a (4methylsulfonylphenyl) imidazole, which does not define a contribution over the prior art. The substituents on the imidazole group vary extensively and when taken as a whole result in vastly different compounds. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper. Additionally, the vastness of the claimed subject matter, the numerous provisos found in the claims, and the complications in understanding the claimed subject matter imposes a burden on any examination of the claimed subject matter.

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal Saeed whose telephone number is (703) 308-4592. The examiner can normally be reached on Monday-Friday from 8:00 AM – 5:00 PM.